How does 2025 flu vaccine effectiveness vary by age group (children, adults, older adults)?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Interim U.S. data for the 2024–25 season show outpatient vaccine effectiveness (VE) estimates ranged roughly 32%–60% in children and adolescents and 36%–54% in adults, while VE against hospitalization in children was substantially higher (63%–78%) and 41%–55% in adults per CDC networks [1]. Southern Hemisphere 2025 estimates and later syntheses indicate about 51% protection against hospitalization in young children but only ~37–38% in older adults, highlighting a consistent pattern: vaccines reduce severe outcomes more reliably than outpatient illness, and protection falls with age [2] [3].
1. What the U.S. interim 2024–25 numbers actually show
CDC’s four-network interim analysis reports heterogeneous VE by age and outcome: in outpatient settings three networks measured 32%, 59%, and 60% VE among children/adolescents, while two networks found 36% and 54% VE among adults; for hospitalizations VE was 63% and 78% in children and 41% and 55% in adults [1]. These are network-specific interim estimates, not a single pooled number, and they show vaccine performance varies by study population and setting [1].
2. Children: decent protection against severe illness, mixed for outpatient disease
Multiple U.S. networks and Southern Hemisphere analyses agree children gain stronger protection against hospitalization than against outpatient visits: U.S. pediatric hospitalization VE reached as high as 78% in one network, and Southern Hemisphere data estimated 51.3% VE against hospitalization in young children [1] [2]. Outpatient VE in children was more variable—some networks reported only ~32% while others reported near 60%—meaning the shot often reduces but does not eliminate mild or medically attended illness [1] [4].
3. Adults (18–64): moderate protection, dependent on network and subtype
Adults’ outpatient VE in 2024–25 sat in an intermediate band—estimates of 36% and 54%—indicating the vaccine cut risk of medically attended illness roughly a third to half in those studies [1]. Network differences, circulating strain mix (A H1N1 vs H3N2), and antigenic match drive that spread; CDC cautions effectiveness varies by season and study design [1].
4. Older adults: lower VE for hospitalization and outpatient illness
Southern Hemisphere interim data and CDC analyses show older adults consistently derive less protection: hospitalization VE was estimated at roughly 37.7% for older adults in southern data [2] [3]. CDC guidance reflects this with preferential recommendations for higher‑dose or adjuvanted vaccines for people ≥65 because those formulations are more effective for that age group [5]. The pattern is consistent: immune aging reduces vaccine-induced protection [5].
5. Why VE differs by age — immunology, vaccine design, and circulating viruses
Available sources attribute age gradients to immune responsiveness (younger people and healthy adults typically mount stronger responses), differences in recommended formulations for older adults (e.g., high‑dose/adjuvanted), and antigenic match between vaccine strains and circulating viruses; CDC emphasizes these factors and seasonal variability as major drivers of VE differences [5] [1]. Southern Hemisphere results underscore that when circulating strains match vaccine components, VE against hospitalization can be around 50% in priority groups but still lower in older adults [2].
6. Conflicting or anomalous studies: one workplace analysis that found negative VE
A Cleveland Clinic preprint reported that, in one working‑age cohort, vaccinated employees had higher influenza incidence and a calculated VE of −26.9% after adjustment [6]. That single observational workplace study reached an unexpected result and its authors acknowledge potential biases (testing differences, other confounders), so it conflicts with multi‑network CDC analyses that show positive VE in adults [6] [1]. Available sources do not mention a definitive, peer‑reviewed overturning of CDC network findings.
7. What the numbers mean for policy and individual decisions
Public‑health reporting across CDC networks and Southern Hemisphere surveillance converges on two policy‑relevant facts: vaccines regularly reduce hospitalizations substantially (often ~40–60% in prioritized groups) and perform less reliably against any outpatient illness [1] [2]. CDC continues to recommend vaccination for everyone ≥6 months and preferential higher‑dose/adjuvanted options for those ≥65 because even modest VE can prevent severe outcomes [7] [5].
8. Limitations, open questions, and what to watch next
Interim VE estimates vary by network, outcome, and time window; CDC cautions these are preliminary and season‑dependent [1]. Southern Hemisphere results offer analogues but are not perfectly predictive of Northern Hemisphere seasons [2]. Watch for finalized CDC VE reports, peer‑reviewed analyses, and updated Southern/Northern surveillance to refine age‑specific VE estimates for 2025–26 [1] [2].
Limitations: this analysis relies on the cited interim CDC reports, Southern Hemisphere summaries, and one workplace preprint; available sources do not mention pooled global meta‑analyses for 2025 that would resolve inter‑network differences.